Condition: Influenza, Human · Sponsor: Seqirus
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| 84046-Accel Research Sites - Birmingham | Birmingham, Alabama, United States | — |
| 84075-Cullman Clinical Trials | Cullman, Alabama, United States | — |
| 84112-DM Clinical Research - Phoenix | Phoenix, Arizona, United States | — |
| 84114-Scottsdale Clinical Trials | Scottsdale, Arizona, United States | — |
| 84045-Lynn Institute of the Ozarks | Little Rock, Arkansas, United States | — |
| 84070-Baptist Health Center for Clinical Research | Little Rock, Arkansas, United States | — |
| 84101-West Coast Research LLC | Dublin, California, United States | — |
| 84124-Leading Edge Research | Encino, California, United States | — |
| 84104-Zillan Clinical Research | Inglewood, California, United States | — |
| 84105-Eximia Research - CA | La Mesa, California, United States | — |
| 84107-Long Beach Research Institute | Long Beach, California, United States | — |
| 84109-Long Beach Clinical Trials | Long Beach, California, United States | — |
+ 243 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.